Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 16/20 | 0.45 |
| ▸ | EDNRA | P25101 | 4/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416654 | 1.00 | CCR4 (0.45) | CCR4EDNRACCR5 | |
| SCHEMBL29749999 | 0.84 | CCR4 (0.41) | CCR4EDNRACCR5 | |
| SCHEMBL376592 | 0.84 | CCR4 (0.41) | CCR4EDNRACCR5 | |
| SCHEMBL29364914 | 0.82 | CCR4 (0.43) | CCR4EDNRACCR5 | |
| SCHEMBL68083 | 0.82 | CCR4 (0.43) | CCR4EDNRACCR5 | |
| SCHEMBL14970085 | 0.82 | CCR4 (0.43) | CCR4EDNRACCR5 | |
| SCHEMBL10085406 | 0.82 | CCR4 (0.40) | CCR4EDNRACCR5 | |
| SCHEMBL23214021 | 0.81 | CCR4 (0.37) | CCR4EDNRACCR5 | |
| SCHEMBL29844738 | 0.81 | CCR4 (0.37) | CCR4EDNRACCR5 | |
| SCHEMBL24722371 | 0.81 | CCR4 (0.40) | CCR4EDNRACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL ENTPR LTD (BM) | 2024-02-08 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
| CN-111971277-B | Benzothiophenes and related compounds as STING agonists | 默沙东有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2398810-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
| US-5011847-A | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | MERCK & CO., INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-5001123-A | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | MERCK & CO., INC. (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0402156-A1 | New 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0402155-A1 | New 2,5-diaryl tetrahydrofurans and analogs therof as PAF antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043386-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SLC47A2 | CCR4 2267/4885EDNRA 237/4885CCR5 671/4885 |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | STING1, IRF3, CGAS | CCR4 2227/4885EDNRA 691/4885CCR5 888/4885 |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | CCR4 4558/4885EDNRA 4029/4885CCR5 3571/4885 |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | CCR4 4779/4885EDNRA 1346/4885CCR5 4076/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | CCR4 679/4885EDNRA 3291/4885CCR5 1279/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | CCR4 2381/4885EDNRA 1926/4885CCR5 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.